C-reactive protein (CRP): more than just an innocent bystander?

References

• de Ferranti SD, Rifai N. C-reactive protein: a nontraditional serum marker of cardiovascular risk. Cardiovasc Pathol 2007;16:14–21
   PubMed Web of Science ®Google Scholar
• Paffen E, Demaat MP. C-reactive protein in atherosclerosis: A causal factor? Cardiovasc Res 2006;71:30–9
   PubMed Web of Science ®Google Scholar
• Osman R, L’Allier PL, Elgharib N, et al. Critical appraisal of C-reactive protein throughout the spectrum of cardiovascular disease. Vasc Health Risk Manag 2006;2:221–37
   PubMedGoogle Scholar
• Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998;97:2007–11
   Google Scholar
• Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998;98:731–3
   PubMed Web of Science ®Google Scholar
• Haverkate F, Thompson SG, Pyke SD, et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997;349:462–6
   PubMed Web of Science ®Google Scholar
• Shankar A, Li J, Nieto FJ, et al. Association between C-reactive protein level and peripheral arterial disease among US adults without cardiovascular disease, diabetes, or hypertension. Am Heart J 2007;154:495–501
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cushman M, Stampfer MJ, et al. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998;97:425–8
   PubMed Web of Science ®Google Scholar
• Winbeck K, Poppert H, Etgen T, et al. Prognostic relevance of early serial C-reactive protein measurements after first ischemic stroke. Stroke 2002;33:2459–64
   PubMed Web of Science ®Google Scholar
• Coppola G, Corrado E, Muratori I, et al. Increased levels of C-reactive protein and fibrinogen influence the risk of vascular events in patients with NIDDM. Int J Cardiol 2006;106:16–20
   PubMed Web of Science ®Google Scholar
• Oren H, Erbay AR, Balci M, et al. Role of novel biomarkers of inflammation in patients with stable coronary heart disease. Angiology 2007;58:148–55
   PubMed Web of Science ®Google Scholar
• Oren H, Erbay AR, Balci M, et al. Role of novel mediators of inflammation in left ventricular remodeling in patients with acute myocardial infarction: do they affect the outcome of patients? Angiology 2007;58:45–54
   PubMed Web of Science ®Google Scholar
• Corrado E, Rizzo M, Tantillo R, et al. Markers of inflammation and infection influence the outcome of patients with baseline asymptomatic carotid lesions: a 5-year follow-up study. Stroke 2006;37:482–6
   PubMed Web of Science ®Google Scholar
• Barutcu I, Sezgin AT, Sezgin N, et al. Increased high sensitive CRP level and its significance in pathogenesis of slow coronary flow. Angiology 2007;58:401–7
   PubMed Web of Science ®Google Scholar
• Linnemann B, Voigt W, Nobel W, et al. C-reactive protein is a strong independent predictor of death in type 2 diabetes: association with multiple facets of the metabolic syndrome. Exp Clin Endocrinol Diabetes 2006;114:127–34
   PubMed Web of Science ®Google Scholar
• Ziakas A, Gavrilidis S, Giannoglou G, et al. In-hospital and long-term prognostic value of fibrinogen, CRP, and IL-6 levels in patients with acute myocardial infarction treated with thrombolysis. Angiology 2006;57:283–93
   PubMed Web of Science ®Google Scholar
• Miller VM, Redfield MM, McConnell JP. Use of BNP and CRP as biomarkers in assessing cardiovascular disease: diagnosis versus risk. Curr Vasc Pharmacol 2007;5:15–25
   Google Scholar
• Suzuki M, Saito M, Nagai T, et al. Systemic versus coronary levels of inflammation in acute coronary syndromes. Angiology 2006;57:459–63
   PubMed Web of Science ®Google Scholar
• Karha J, Bavry AA, Rajagopal V, et al. Relation of C-reactive protein level and long-term risk of death or myocardial infarction following percutaneous coronary intervention with a sirolimus-eluting stent. Am J Cardiol 2006;98:616–8
   PubMed Web of Science ®Google Scholar
• Hong YJ, Jeong MH, Lim SY, et al. Relation of soft plaque and elevated preprocedural high-sensitivity C-reactive protein levels to incidence of in-stent restenosis after successful coronary artery stenting. Am J Cardiol 2006;98:341–5
   PubMed Web of Science ®Google Scholar
• Palmerini T, Marzocchi A, Marrozzini C, et al. Preprocedural levels of C-reactive protein and leukocyte counts predict 9-month mortality after coronary angioplasty for the treatment of unprotected left main coronary artery stenosis. Circulation 2005;112:2332–8
   PubMed Web of Science ®Google Scholar
• Li JJ, Fang CH, Jiang H, et al. Increased C-reactive protein level after renal stent implantation in patients with atherosclerotic renal stenosis. Angiology 2004;55:479–84
   PubMed Web of Science ®Google Scholar
• Fatourou EM, Paraskevas KI, Seifalian AM, et al. The role of established and emerging risk factors in peripheral vascular graft occlusion. Expert Opin Pharmacother 2007;8:901–11
   PubMed Web of Science ®Google Scholar
• Owens CD, Ridker PM, Belkin M, et al. Elevated C-reactive protein levels are associated with postoperative events in patients undergoing lower extremity vein bypass surgery. J Vasc Surg 2007;45:2–9
   PubMed Web of Science ®Google Scholar
• Abdellaoui A, Al-Khaffaf H. C-reactive protein (CRP) as a marker in peripheral vascular disease. Eur J Vasc Endovasc Surg 2007;34:18–22
   PubMed Web of Science ®Google Scholar
• Lusic I, Radonic V, Pavelin S, et al. Is C-reactive protein a better predictor of recurrent carotid disease following carotid endarterectomy than established risk factors for atherosclerosis? Vasa 2006;35:221–5
   PubMed Web of Science ®Google Scholar
• Heider P, Poppert H, Wolf O, et al. Fibrinogen and high-sensitive C-reactive protein as serologic predictors for perioperative cerebral microembolic lesions after carotid endarterectomy. J Vasc Surg 2007;46:449–54
   PubMed Web of Science ®Google Scholar
• Pitsavos C, Panagiotakos DB, Tzima N, et al. Diet, exercise, and C-reactive protein levels in people with abdominal obesity: the ATTICA epidemiological study. Angiology 2007;58:225–33
   PubMed Web of Science ®Google Scholar
• Smith SC Jr, Haslam D. Abdominal obesity, waist circumference and cardio-metabolic risk: awareness among primary care physicians, the general population and patients at risk – the Shape of the Nations survey. Curr Med Res Opin 2007;23:29–47
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS, Ganotakis ES, Mikhailidis DP. Shape of the Nations survey and attitudes to cardiometabolic risk. Curr Med Res Opin 2007;23:25–8
   PubMed Web of Science ®Google Scholar
• Guven A, Cetinkaya A, Aral M, et al. High-sensitivity C-reactive protein in patients with metabolic syndrome. Angiology 2006;57:295–302
   PubMed Web of Science ®Google Scholar
• Efstratiadis G, Tsiaousis G, Athyros VG, et al. Total serum insulin-like growth factor-1 and C-reactive protein in metabolic syndrome with or without diabetes. Angiology 2006;57:303–11
   PubMed Web of Science ®Google Scholar
• Gazi IF, Mikhailidis DP. Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview. Expert Opin Ther Targets 2006;10:851–66
   PubMed Web of Science ®Google Scholar
• Ose L, Shah A, Davies MJ, et al. Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis. Curr Med Res Opin 2006;22:823–35
   PubMed Web of Science ®Google Scholar
• Catapano AL, Davidson MH, Ballantyne CM, et al. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin 2006;22:2041–53
   PubMed Web of Science ®Google Scholar
• Goldstein BJ, Weissman PN, Wooddell MJ, et al. Reductions in biomarkers of cardiovascular risk in type 2 diabetes with rosiglitazone added to metformin compared with dose escalation of metformin: an EMPIRE trial sub-study. Curr Med Res Opin 2006;22:1715–23
   PubMed Web of Science ®Google Scholar
• Stewart MW, Cirkel DT, Furuseth K, et al. Effect of metformin plus roziglitazone compared with metformin alone on glycaemic control in well-controlled Type 2 diabetes. Diabet Med 2006;23:1069–78
   PubMed Web of Science ®Google Scholar
• Kakafika AI, Mikhailidis DP, Karagiannis A, et al. The role of endocannabinoid system blockade in the treatment of the metabolic syndrome. J Clin Pharmacol 2007;47:642–52
   PubMed Web of Science ®Google Scholar
• Chang TY, Chou KJ, Tseng CF, et al. Effects of folic acid and vitamin B complex on serum C-reactive protein and albumin levels in stable hemodialysis patients. Curr Med Res Opin 2007;23:1879–86
   PubMed Web of Science ®Google Scholar
• Tunez I, Feijoo M, Huerta G, et al. The effect of infliximab on oxidative stress in chronic inflammatory joint disease. Curr Med Res Opin 2007;23:1259–67
   PubMed Web of Science ®Google Scholar
• Milionis HJ, Rizos E, Kostapanos M, et al. Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). Curr Med Res Opin 2006;22:1123–31
   PubMed Web of Science ®Google Scholar
• Tsiara S, Elisaf M, Mikhailidis DP. Early vascular benefits of statin therapy. Curr Med Res Opin 2003;19:540–56
   PubMed Web of Science ®Google Scholar
• Athyros VG, Mikhailidis DP, Didangelos TP, et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin 2006;22:873–83
   PubMed Web of Science ®Google Scholar
• Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. Targeting vascular risk in patients with metabolic syndrome but without diabetes. Metabolism 2005;54:1065–74
   PubMed Web of Science ®Google Scholar
• Ilerigelen B, Uresin Y, San M, et al. TULIPS Investigators. Efficacy and safety of extended-release fluvastatin in Turkish patients with hypercholesterolaemia: TULIPS (Turkish Lipid Study). Curr Med Res Opin 2007;23:1093–102
   Google Scholar
• Li JJ, Fang CH, Qian HY, et al. Time course of rapid C-reactive protein reduction by pravastatin in patients with stable angina. Angiology 2006;57:1–7
   PubMed Web of Science ®Google Scholar
• Tsimihodimos V, Kostoula A, Kakafika A, et al. Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values. J Cardiovasc Pharmacol Ther 2004;9:27–33
   PubMed Web of Science ®Google Scholar
• Rizos E, Bairaktari E, Ganotakis E, et al. Effects of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes. J Cardiovasc Pharmacol Ther 2002;7:219–26
   PubMedGoogle Scholar
• Rizos E, Kostoula A, Elisaf M, et al. Effect of ciprofibrate on C-reactive protein and fibrinogen levels. Angiology 2002;53:273–7
   PubMed Web of Science ®Google Scholar
• Prasad K. C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev 2006;24:33–50
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, Gallimore JR, Kahan MC, et al. Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 2005;102:8309–14
   PubMed Web of Science ®Google Scholar
• Lowe GD, Pepys MB. C-reactive protein and cardiovascular disease: weighing the evidence. Curr Atheroscler Rep 2006;8:421–8
   PubMedGoogle Scholar
• Tennent GA, Hutchinson WL, Kahan MC, et al. Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE(−/−) mice. Atherosclerosis 2007 [Epub ahead of print 21 Jun 2007]
   Google Scholar
• Casas JP, Shah T, Cooper J, et al. Insight into the nature of the CRP-coronary event association using Mendelian randomization. Int J Epidemiol 2006;35:922–31
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, Herbert J, Kahan MC, et al. Human C-reactive protein does not protect against acute lipopolysaccharide challenge in mice. J Immunol 2003;171:6046–51
   PubMed Web of Science ®Google Scholar
• Clapp BR, Hirschfield GM, Storry C, et al. Inflammation and endothelial function: direct vascular effects of human C-reactive protein on nitric oxide bioavailability. Circulation 2005;111:1530–6
   PubMed Web of Science ®Google Scholar
• Bisoendial RJ, Kastelein JJ, Levels JH, et al. Activation of inflammation and coagulation after infusion of C-reactive protein in humans. Circ Res 2005;96:714–6
   PubMed Web of Science ®Google Scholar
• Pepys MB. CRP or not CRP? That is the question. Arterioscler Thromb Vasc Biol 2005;25:1091–4
   PubMed Web of Science ®Google Scholar
• Saxena U. A new therapeutic target for atherosclerosis treatment: interview with Uday Saxena. Interviewed by Emma Quigley. Expert Opin Ther Targets 2006;10:1–3
   PubMed Web of Science ®Google Scholar
• Suckling KE. The return of two old targets? Expert Opin Ther Targets 2006;10:785–8
   PubMed Web of Science ®Google Scholar
• Tiwari A. Statins and telomere length: risk assessment and management of coronary artery disease. Expert Opin Ther Targets 2006;11:972–82
   Web of Science ®Google Scholar
• Suckling K. The continuing complexes of high-density lipoprotein metabolism in drug discovery and development. Expert Opin Ther Targets 2007;11:1133–6
   PubMed Web of Science ®Google Scholar
• Tziomalos K, Athyros VG, Karagiannis A, et al. Endothelial function, arterial stiffness and lipid lowering drugs. Expert Opin Ther Targets 2007;11:1143–60
   PubMed Web of Science ®Google Scholar
• Salh B. c-Jun N-terminal kinases as potential therapeutic targets. Expert Opin Ther Targets 2007;11:1139–53
   Web of Science ®Google Scholar
• Jeyaseelan K, Herath WB, Armugam A. MicroRNAs as therapeutic targets in human diseases. Expert Opin Ther Targets 2007;11:1119–29
   PubMed Web of Science ®Google Scholar
• Ludwig RJ, Schon MP, Boehncke WH. P-selectin: a common therapeutic target for cardiovascular disorders, inflammation and tumour metastasis. Expert Opin Ther Targets 2007;11:1103–17
   PubMed Web of Science ®Google Scholar
• Ouchi N, Shibata R, Walsh K. Targeting adiponectin for cardioprotection. Expert Opin Ther Targets 2006;10: 573–81
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cannon CP, Morrow D, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20–8
   Google Scholar